---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-026107"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:56:08.819423+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q1 net loss $10.6M; VERSATILE-002 shows median OS of 30 months in HNSCC

## Summary
- VERSATILE-002 Phase 2: median overall survival 30 months (vs 7-18 months for ICIs); BOR 34% (CPS≥1), 48% (CPS≥20).
- Updated registrational trial strategy: triple combination Versamune HPV + PDS01ADC + pembrolizumab in first-line HNSCC.
- Appointed Stephan Toutain as COO; brings commercial experience.
- Two patents granted by Israel and Australia extending Versamune platform protection through 2036-2038.
- Q1 net loss $10.6M ($0.30/share); cash $66.6M; R&D expenses $6.7M.

## SEC filing metadata
- accession: 0001140361-24-026107
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/0001140361-24-026107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/ef20029143_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-026107
- JSON: https://secwatch.observer/filing/0001140361-24-026107.json
- Plain text: https://secwatch.observer/filing/0001140361-24-026107.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported the three months ended March 31, 2024 results: net income approximately $10.6 million, EPS $0.30 per basic share and diluted share.
  - Period: the three months ended March 31, 2024
  - Net income: approximately $10.6 million
  - EPS: $0.30 per basic share and diluted share
  - Result: reported results
  source text: Reported net loss was approximately $10.6 million, or $0.30 per basic share and diluted share, for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/0001140361-24-026107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.